Economic Consequences of Major Depressive Disorder

PharmacoEconomics invites the submission of papers (original research, reviews, opinion and tutorial pieces) on the economic consequences of major depressive disorder (MDD) for a themed issue of the journal to be published in 2021 and guest edited by Paul Greenberg (Analysis Group). We encourage papers from the perspectives from a variety of stakeholders including payers, health technology assessment bodies, health economists, clinicians, pharmaceutical industry, policy makers, patients and caregivers, and advocacy groups. Special patient population perspectives (e.g. youth, comorbid populations, aged) and papers employing novel methods are particularly encouraged. Papers can be either methodological or applied.

Topics of interest include:

  • Epidemiologic estimates of MDD and its treatment
  • Economic and Humanistic Burden
    • Direct and indirect costs
    • Employment effects
    • Spillover effects
    • Quality of Life
  • Cost Effectiveness of Treatment
    • Models, trials or database analyses
  • Stated Preferences
    • Discrete choice experiments
    • Utility estimation
  • Methodological Challenges
    • Special patient populations
    • Impact of adherence
    • Modelling (treatment sequences, combination treatment, defining health states)
    • Challenges in conducting database analyses
    • Estimating workplace burden
    • Precision medicine
    • Placebo effects
    • Behavioural interventions
    • Treatment adverse effects
    • Distinguishing PRO and QALY data from data gathered using diagnostic instruments

Please submit an abstract describing your proposed paper by June 30th, 2020 to Full papers will be invited by July 31st 2020 and manuscripts due by November 30th 2020

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.